HC Wainwright Reaffirms Buy Rating for Celldex Therapeutics (NASDAQ:CLDX)

HC Wainwright reaffirmed their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX - Free Report) in a research report sent to investors on Thursday,Benzinga reports. HC Wainwright currently has a $80.00 price target on the biopharmaceutical company's stock.

A number of other research firms also recently weighed in on CLDX. Wells Fargo & Company raised Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Thursday, September 26th. Wolfe Research cut shares of Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a research note on Friday, September 27th. Cantor Fitzgerald restated an "overweight" rating and set a $67.00 target price on shares of Celldex Therapeutics in a research report on Monday, September 16th. Citigroup assumed coverage on shares of Celldex Therapeutics in a research report on Monday, October 7th. They issued a "buy" rating and a $70.00 price target on the stock. Finally, The Goldman Sachs Group initiated coverage on shares of Celldex Therapeutics in a research note on Monday, September 30th. They set a "neutral" rating and a $45.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $62.25.

Celldex Therapeutics Stock Performance

Shares of NASDAQ CLDX traded up $0.56 during midday trading on Thursday, hitting $25.38. 847,310 shares of the stock traded hands, compared to its average volume of 886,518. The firm has a market capitalization of $1.68 billion, a P/E ratio of -9.88 and a beta of 1.57. Celldex Therapeutics has a one year low of $22.93 and a one year high of $53.18. The firm has a 50-day moving average of $27.00 and a two-hundred day moving average of $33.47.

Insiders Place Their Bets

In other Celldex Therapeutics news, CEO Anthony S. Marucci acquired 11,500 shares of the company's stock in a transaction dated Monday, November 11th. The stock was purchased at an average price of $26.82 per share, with a total value of $308,430.00. Following the completion of the purchase, the chief executive officer now directly owns 40,284 shares in the company, valued at approximately $1,080,416.88. The trade was a 39.95 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 3.80% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CLDX. KBC Group NV grew its holdings in Celldex Therapeutics by 31.2% during the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company's stock valued at $71,000 after buying an additional 495 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Celldex Therapeutics during the second quarter valued at $76,000. Los Angeles Capital Management LLC increased its holdings in Celldex Therapeutics by 9.5% in the 2nd quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company's stock valued at $273,000 after acquiring an additional 638 shares during the last quarter. Quest Partners LLC lifted its stake in Celldex Therapeutics by 1,364.9% in the 2nd quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company's stock worth $273,000 after purchasing an additional 6,879 shares in the last quarter. Finally, AQR Capital Management LLC boosted its holdings in shares of Celldex Therapeutics by 23.7% during the 2nd quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company's stock valued at $291,000 after purchasing an additional 1,504 shares during the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.